journal
MENU ▼
Read by QxMD icon Read
search

Lancet. Gastroenterology & Hepatology

journal
https://www.readbyqxmd.com/read/29754836/misoprostol-for-small-bowel-ulcers-in-patients-with-obscure-bleeding-taking-aspirin-and-non-steroidal-anti-inflammatory-drugs-masters-a-randomised-double-blind-placebo-controlled-phase-3-trial
#1
Ali S Taha, Caroline McCloskey, Paula McSkimming, Alex McConnachie
BACKGROUND: The incidence of obscure gastrointestinal bleeding, which originates from the small bowel and is mainly associated with the use of aspirin and non-steroidal anti-inflammatory drugs (NSAIDs), is rising. We assessed the efficacy and safety of misoprostol for the treatment of small bowel ulcers and erosions in patients taking low-dose aspirin or NSAIDs with obscure gastrointestinal bleeding. METHODS: In this randomised, double-blind, placebo-controlled, phase 3 trial, we recruited patients (aged ≥18 years) with small bowel ulcers who were taking low-dose aspirin, NSAIDs, or both for a minimum of 4 weeks, at University Hospital Crosshouse (Kilmarnock, UK)...
May 10, 2018: Lancet. Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/29753671/misoprostol-for-nsaid-induced-small-bowel-erosions-and-ulcers
#2
Timothy A Rockall
No abstract text is available yet for this article.
May 9, 2018: Lancet. Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/29730082/endophenotyping-eosinophilic-oesophagitis-a-new-era-for-management
#3
Simon Keely, Nicholas J Talley
No abstract text is available yet for this article.
May 2, 2018: Lancet. Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/29730081/eosinophilic-oesophagitis-endotype-classification-by-molecular-clinical-and-histopathological-analyses-a-cross-sectional-study
#4
Tetsuo Shoda, Ting Wen, Seema S Aceves, J Pablo Abonia, Dan Atkins, Peter A Bonis, Julie M Caldwell, Kelley E Capocelli, Christina L Carpenter, Margaret H Collins, Evan S Dellon, Michael D Eby, Nirmala Gonsalves, Sandeep K Gupta, Gary W Falk, Ikuo Hirano, Paul Menard-Katcher, Jonathan T Kuhl, Jeffrey P Krischer, John Leung, Vincent A Mukkada, Jonathan M Spergel, Michael P Trimarchi, Guang-Yu Yang, Nives Zimmermann, Glenn T Furuta, Marc E Rothenberg
BACKGROUND: Eosinophilic oesophagitis is understood in terms of quantifiable histological, endoscopic, and molecular features. Data are scant for inter-relations of these features and their potential to identify distinct disease endotypes. We aimed to identify clinical-pathological correlations between endoscopic and histological disease variables by transcription profiling of the oesophagus of patients with eosinophilic oesophagitis of varying severity and disease activity states. METHODS: We did a cross-sectional study across ten hospital sites in the USA associated with the Consortium of Eosinophilic Gastrointestinal Disease Researchers...
May 2, 2018: Lancet. Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/29709559/the-end-of-bursectomy-for-gastric-cancer
#5
Ben E Byrne, Chris A Rogers, Jane M Blazeby
No abstract text is available yet for this article.
April 27, 2018: Lancet. Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/29709558/bursectomy-versus-omentectomy-alone-for-resectable-gastric-cancer-jcog1001-a-phase-3-open-label-randomised-controlled-trial
#6
Yukinori Kurokawa, Yuichiro Doki, Junki Mizusawa, Masanori Terashima, Hitoshi Katai, Takaki Yoshikawa, Yutaka Kimura, Shuji Takiguchi, Yasunori Nishida, Norimasa Fukushima, Yoshiaki Iwasaki, Masahide Kaji, Motohiro Hirao, Hiroshi Katayama, Mitsuru Sasako
BACKGROUND: The role of bursectomy, in which the peritoneal lining covering the pancreas and the anterior plane of the transverse mesocolon are dissected, has long been controversial for preventing peritoneal metastasis. We investigated the survival benefit of bursectomy in patients with resectable gastric cancer. METHODS: This phase 3, open-label, randomised controlled trial was done at 57 hospitals in Japan. Patients aged 20-80 years who had cT3(SS)-cT4a(SE) histologically proven gastric adenocarcinoma with an Eastern Cooperative Oncology Group performance status of 0 or 1 and body-mass index less than 30 kg/m2 and who did not have distant metastasis or bulky lymph nodes were randomly assigned (1:1) during surgery to receive omentectomy alone (non-bursectomy) or bursectomy...
April 27, 2018: Lancet. Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/29706559/palb2-as-a-familial-gastric-cancer-gene-is-the-wait-over
#7
Luis G Carvajal-Carmona
No abstract text is available yet for this article.
April 26, 2018: Lancet. Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/29706558/germline-pathogenic-variants-in-palb2-and-other-cancer-predisposing-genes-in-families-with-hereditary-diffuse-gastric-cancer-without-cdh1-mutation-a-whole-exome-sequencing-study
#8
Eleanor Fewings, Alexey Larionov, James Redman, Mae A Goldgraben, James Scarth, Susan Richardson, Carole Brewer, Rosemarie Davidson, Ian Ellis, D Gareth Evans, Dorothy Halliday, Louise Izatt, Peter Marks, Vivienne McConnell, Louis Verbist, Rebecca Mayes, Graeme R Clark, James Hadfield, Suet-Feung Chin, Manuel R Teixeira, Olivier T Giger, Richard Hardwick, Massimiliano di Pietro, Maria O'Donovan, Paul Pharoah, Carlos Caldas, Rebecca C Fitzgerald, Marc Tischkowitz
BACKGROUND: Germline pathogenic variants in the E-cadherin gene (CDH1) are strongly associated with the development of hereditary diffuse gastric cancer. There is a paucity of data to guide risk assessment and management of families with hereditary diffuse gastric cancer that do not carry a CDH1 pathogenic variant, making it difficult to make informed decisions about surveillance and risk-reducing surgery. We aimed to identify new candidate genes associated with predisposition to hereditary diffuse gastric cancer in affected families without pathogenic CDH1 variants...
April 26, 2018: Lancet. Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/29680474/the-international-liver-congress-2018
#9
Rob Brierley
No abstract text is available yet for this article.
April 18, 2018: Lancet. Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/29631811/sorafenib-and-hepatic-arterial-infusion-chemotherapy-another-failed-combination
#10
Tim Meyer
No abstract text is available yet for this article.
April 6, 2018: Lancet. Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/29631810/sorafenib-plus-low-dose-cisplatin-and-fluorouracil-hepatic-arterial-infusion-chemotherapy-versus-sorafenib-alone-in-patients-with-advanced-hepatocellular-carcinoma-silius-a-randomised-open-label-phase-3-trial
#11
Masatoshi Kudo, Kazuomi Ueshima, Osamu Yokosuka, Sadahisa Ogasawara, Shuntaro Obi, Namiki Izumi, Hiroshi Aikata, Hiroaki Nagano, Etsuro Hatano, Yutaka Sasaki, Keisuke Hino, Takashi Kumada, Kazuhide Yamamoto, Yasuharu Imai, Shouta Iwadou, Chikara Ogawa, Takuji Okusaka, Fumihiko Kanai, Kohei Akazawa, Ken-Ichi Yoshimura, Philip Johnson, Yasuaki Arai
BACKGROUND: Hepatic arterial infusion chemotherapy plus sorafenib in phase 2 trials has shown favourable tumour control and a manageable safety profile in patients with advanced, unresectable hepatocellular carcinoma. However, no randomised phase 3 trial has tested the combination of sorafenib with continuous arterial infusion chemotherapy. We aimed to compare continuous hepatic arterial infusion chemotherapy plus sorafenib with sorafenib alone in patients with advanced, unresectable hepatocellular carcinoma...
April 6, 2018: Lancet. Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/29625842/shifting-the-treatment-model-for-resectable-pancreatic-cancer
#12
Andrew H Ko
No abstract text is available yet for this article.
April 3, 2018: Lancet. Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/29625841/safety-and-efficacy-of-preoperative-or-postoperative-chemotherapy-for-resectable-pancreatic-adenocarcinoma-pact-15-a-randomised-open-label-phase-2-3-trial
#13
Michele Reni, Gianpaolo Balzano, Silvia Zanon, Alessandro Zerbi, Lorenza Rimassa, Renato Castoldi, Domenico Pinelli, Stefania Mosconi, Claudio Doglioni, Marta Chiaravalli, Chiara Pircher, Paolo Giorgio Arcidiacono, Valter Torri, Paola Maggiora, Domenica Ceraulo, Massimo Falconi, Luca Gianni
BACKGROUND: Pancreatic ductal adenocarcinoma are known to metastasise early and a rationale exists for the investigation of preoperative chemotherapy in patients with resectable disease. We aimed to assess the role of combination chemotherapy in this setting in the PACT-15 trial. METHODS: We did this randomised, open-label, phase 2-3 trial in ten hospitals in Italy. We report the phase 2 part here. Patients aged 18-75 years who were previously untreated for pancreatic ductal adenocarcinoma, with Karnofsky performance status of more than 60, and pathologically confirmed stage I-II resectable disease were enrolled...
April 3, 2018: Lancet. Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/29606564/serum-concentrations-after-switching-from-originator-infliximab-to-the-biosimilar-ct-p13-in-patients-with-quiescent-inflammatory-bowel-disease-secure-an-open-label-multicentre-phase-4-non-inferiority-trial
#14
Anne S Strik, Wim van de Vrie, Joanne P J Bloemsaat-Minekus, Michael Nurmohamed, Peter J J Bossuyt, Alexander Bodelier, Theo Rispens, Yvonne J B van Megen, Geert R D'Haens
BACKGROUND: Biological treatment of chronic inflammatory diseases has improved patient outcomes but increased health-care costs. Switching patients from originator infliximab to a biosimilar can reduce costs, but prospective data about pharmacokinetics and potential immunogenicity are scarce. We aimed to show that infliximab serum concentrations with biosimilar CT-P13 are non-inferior to those with originator infliximab after switching from originator infliximab in patients with inflammatory bowel disease...
March 29, 2018: Lancet. Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/29599078/global-prevalence-treatment-and-prevention-of-hepatitis-b-virus-infection-in-2016-a-modelling-study
#15
(no author information available yet)
BACKGROUND: The 69th World Health Assembly approved the Global Health Sector Strategy to eliminate viral hepatitis by 2030. Although no virological cure exists for hepatitis B virus (HBV) infection, existing therapies to control viral replication and prophylaxis to minimise mother-to-child transmission make elimination of HBV feasible. We aimed to estimate the national, regional, and global prevalence of HBsAg in the general population and in the population aged 5 years in 2016, as well as coverage of prophylaxis, diagnosis, and treatment...
March 26, 2018: Lancet. Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/29599077/delineating-the-global-challenges-of-hepatitis-b-virus-infection
#16
Geoffrey Dusheiko, Kosh Agarwal
No abstract text is available yet for this article.
March 26, 2018: Lancet. Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/29567005/is-autofluorescence-inferior-to-chromoendoscopy-for-dysplasia-detection-in-ulcerative-colitis
#17
Michael F Picco
No abstract text is available yet for this article.
March 19, 2018: Lancet. Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/29739676/correction-to-lancet-gastroenterol-hepatol-2018-3-337-48
#18
(no author information available yet)
No abstract text is available yet for this article.
June 2018: Lancet. Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/29739675/white-oesophagus
#19
Konstantinos Blouhos, Konstantinos A Boulas, Konstantinos Tsalis, Anestis Hatzigeorgiadis
No abstract text is available yet for this article.
June 2018: Lancet. Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/29739674/diffusion-weighted-mri-in-inflammatory-bowel-disease
#20
REVIEW
Lieven Pouillon, Valérie Laurent, Marc Pouillon, Peter Bossuyt, Christiana Bonifacio, Silvio Danese, Parakkal Deepak, Edward V Loftus, David H Bruining, Laurent Peyrin-Biroulet
Cross-sectional MRI is an attractive alternative to endoscopy for the objective assessment of patients with inflammatory bowel disease (IBD). Diffusion-weighted imaging is a specialised technique that maps the diffusion of water molecules in biological tissues and can be done without intravenous gadolinium contrast injection. Diffusion-weighted imaging further expands the capability of traditional MRI sequences in IBD. However, the use of quantitative parameters, such as the apparent diffusion coefficient, is limited by low reproducibility...
June 2018: Lancet. Gastroenterology & Hepatology
journal
journal
53645
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"